A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity

Combinatorial strategies, such as targeting different immune checkpoint receptors, hold promise to increase the breadth and duration of the response to cancer therapy. Here we describe the preclinical evaluation of CTX-8371, a protein construct which combines PD-1 and PD-L1 targeting in one bispecif...

Full description

Bibliographic Details

Published in:	Oncoimmunology Vol. 13; no. 1; p. 2316945
Main Authors:	Albu, Diana I, Wolf, Benjamin J, Qin, Yan, Wang, Xianzhe, Daniel Ulumben, Amy, Su, Mei, Li, Vivian, Ding, Eirene, Angel Gonzalo, Jose, Kong, Jason, Jadhav, Ruturaj, Kuklin, Nelly, Visintin, Alberto, Gong, Bing, Schuetz, Thomas J
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis 2024 Taylor & Francis Group
Subjects:	Animals Antibodies, Bispecific - pharmacology Antibodies, Bispecific - therapeutic use B7-H1 Antigen Cancer immunotherapy immuno-oncology Lung Neoplasms Lymphocyte Activation Mice Programmed Cell Death 1 Receptor Special Report Cancer immunotherapy immuno-oncology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!